Marianne Habdank

发表

TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.

Verena I Gaidzik, Lars Bullinger, Hartmut Döhner, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Manuela Zucknick, Verena I Gaidzik, Lars Bullinger, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CEBPA Germline Mutation Screening in Cytogenetically Normal Acute Myeloid Leukemia with Somatically Acquired CEBPA Mutations.

S. Fröhling, K. Döhner, R. Schlenk, 2007 .

Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML): Results of the AML Study Group (AMLSG)

K. Döhner, R. Schlenk, A. Ganser, 2008 .

The Genotype NPM1mut/FLT3-ITDneg Is a Highly Significant Predictive Factor for Response to Therapy with All-Trans Retinoic Acid in Acute Myeloid Leukemia - Results from AMLSG Trial AML HD98B.

S. Fröhling, K. Döhner, R. Schlenk, 2007 .

TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.

S. Fröhling, L. Bullinger, K. Döhner, 2012, Blood.

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B

S. Fröhling, L. Bullinger, K. Döhner, 2009, Haematologica.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Axel Benner, Stefan Fröhling, Lars Bullinger, 2008, The New England journal of medicine.

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

K. Döhner, R. Schlenk, H. Döhner, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Stefan Fröhling, Lars Bullinger, Claudia Scholl, 2005, Blood.

High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations

L. Bullinger, K. Döhner, H. Döhner, 2010, Haematologica.

Detection of RAS, KIT and FLT3 Gene Mutations in t(8;21)-Positive Acute Myeloid Leukemia (AML): Evaluation of the Clinical Relevance.

S. Fröhling, L. Bullinger, K. Döhner, 2006 .

Clinical Impact of WT1 Mutations in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSG).

K. Döhner, R. Schlenk, H. Döhner, 2007 .

TET2 Mutations In Acute Myeloid Leukemia (AML): Results on 783 Patients Treated within the AML HD98A Study of the AML Study Group (AMLSG)

L. Bullinger, K. Döhner, R. Schlenk, 2010 .

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

S. Fröhling, L. Bullinger, K. Döhner, 2005, Blood.

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B

S. Fröhling, L. Bullinger, K. Döhner, 2009, Haematologica.